Biogen Idec (BIIB) gathered investors together Wednesday to pitch the company's research pipeline and stifle concerns that its leading position in the multiple sclerosis treatment market was vulnerable to competition.
A phase III study of a long-acting version of Avonex, the company's top-selling multiple sclerosis drug, will begin in the middle of the year, the company announced. The drug, called PEG-Avonex, aims to be more convenient than but equally effective as Avonex, Biogen Idec's most important drug with $2.2 billion in sales last year.
Multiple sclerosis patients will take PEG-Avonex by injection every two weeks or every four weeks instead of the weekly injection required for Avonex.
Biogen Idec also said that patient enrollment has completed in the first of two phase III studies of the company's oral multiple sclerosis drug known as BG-12.Both BG-12 and PEG-Avonex are important for Biogen Idec's future growth because of competition from Novartis (NVS) and the German drug maker Merck KGaA, which are developing oral multiple sclerosis drugs of their own. Both the Novartis drug, known as FTY720, and the Merck drug, cladribine, have posted positive results in phase III studies, and both companies have already announced plans to seek regulatory approval later this year. All current multiple sclerosis drugs, including Biogen's Avonex and Tysabri, which it co-markets with Elan (ELN), are administered by injections, which leaves them commercially vulnerable to an oral multiple sclerosis drug, if one can be approved that is equally or more effective with an acceptable safety profile.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV